The first Budget of the new government will be presented this Wednesday. It’s an important moment, not just for life sciences but for the broader UK economy. Read this blog for an update on the Life Sciences Council, and the launch of our latest Influencing and shaping our sector report.
Astex Pharmaceuticals announced today that it will make five key data presentations at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics, 23rd-25th October 2024, Barcelona, Spain.
Attending the BIA’s TechBio UK conference this year offered an incredible opportunity to witness the ingenuity and innovation driving the future of life sciences.
Ikarovec’s seed round extension raises funds to continue advanced pre-clinical trials of novel gene therapies to treat blindness and major chronic eye disease.
The Innovation in Life Sciences funding call seeks applications from organisations in the life sciences sector to create HNCDI projects that apply emerging digital technologies to industrially relevant and impactful research and innovation to further drug discovery and precision medicine in the UK.
Laverock Therapeutics today announces it is to present new data on its innovative gene-silencing platform at the European Society of Gene & Cell Therapy (ESGCT) Conference in Rome 22-25 October.
The UK biotech sector demonstrated encouraging resilience in the third quarter of 2024 raising a total of £808 million in venture capital and public financing. Read our latest report to find out more.
The UK biotech sector secured an impressive £808 million in Q3 2024, defying tough global market conditions and demonstrating sustained investor confidence. Read our latest report to find out more.
This is part of a series of blogs focussing on hearing therapeutics from different sector perspectives. In this blog, Karen Steel shares her thoughts on what she perceives to be some of the biggest opportunities in relation to the development of new treatments for hearing loss.
A new group of MPs and peers, with the support of the BioIndustry Association (BIA), has written to the Chancellor, urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget.
eXmoor and Virica receive funding to improve AAV gene therapy manufacturing. Partners will develop formulations of VSEs™ and validate their ability to improve yields of adeno-associated vector (AAVs) at scale, lowering gene therapy costs at commercial scale. Virica and eXmoor will receive advisory services and funding through collaborative Canada-UK government program.